ES2645431T3 - Polipéptido de fusión fluorescente, biosensor que comprende dicho polipéptido y usos de los mismos - Google Patents
Polipéptido de fusión fluorescente, biosensor que comprende dicho polipéptido y usos de los mismos Download PDFInfo
- Publication number
- ES2645431T3 ES2645431T3 ES13739169.4T ES13739169T ES2645431T3 ES 2645431 T3 ES2645431 T3 ES 2645431T3 ES 13739169 T ES13739169 T ES 13739169T ES 2645431 T3 ES2645431 T3 ES 2645431T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- seq
- fluorescent
- fusion polypeptide
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 301
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 102
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 99
- 230000004927 fusion Effects 0.000 title claims abstract description 78
- 210000004027 cell Anatomy 0.000 claims abstract description 80
- 230000014759 maintenance of location Effects 0.000 claims abstract description 71
- 238000010361 transduction Methods 0.000 claims abstract description 70
- 230000026683 transduction Effects 0.000 claims abstract description 70
- 239000012528 membrane Substances 0.000 claims abstract description 61
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 30
- 230000003834 intracellular effect Effects 0.000 claims abstract description 28
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 7
- 210000003660 reticulum Anatomy 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 229910052791 calcium Inorganic materials 0.000 claims description 28
- 239000011575 calcium Substances 0.000 claims description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 27
- 230000004224 protection Effects 0.000 claims description 18
- 102000000584 Calmodulin Human genes 0.000 claims description 16
- 108010041952 Calmodulin Proteins 0.000 claims description 16
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 16
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 16
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 claims description 15
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 claims description 15
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 150000001982 diacylglycerols Chemical class 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 101150005609 MED20 gene Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- VBMOHECZZWVLFJ-GXTUVTBFSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]hexan Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCCN VBMOHECZZWVLFJ-GXTUVTBFSA-N 0.000 claims 1
- 108010068904 lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine Proteins 0.000 claims 1
- 230000004807 localization Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 description 15
- 238000002952 image-based readout Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 10
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 10
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 10
- 102100024304 Protachykinin-1 Human genes 0.000 description 10
- 101800003906 Substance P Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 238000010191 image analysis Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101150044980 Akap1 gene Proteins 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940039009 isoproterenol Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 102100037346 Substance-P receptor Human genes 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102100024049 A-kinase anchor protein 13 Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 101100181139 Drosophila melanogaster Pkcdelta gene Proteins 0.000 description 2
- 101100269519 Homo sapiens AKAP13 gene Proteins 0.000 description 2
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 2
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 2
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 2
- 101710149430 Tachykinin-1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- -1 cAMP Chemical compound 0.000 description 2
- 230000036978 cell physiology Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382272 | 2012-07-06 | ||
| EP12382272 | 2012-07-06 | ||
| PCT/EP2013/064400 WO2014006225A1 (en) | 2012-07-06 | 2013-07-08 | Fluorescent fusion polypeptide, biosensor comprising said polypeptide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2645431T3 true ES2645431T3 (es) | 2017-12-05 |
Family
ID=48803514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13739169.4T Active ES2645431T3 (es) | 2012-07-06 | 2013-07-08 | Polipéptido de fusión fluorescente, biosensor que comprende dicho polipéptido y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9784728B2 (enExample) |
| EP (1) | EP2870475B1 (enExample) |
| JP (1) | JP6393260B2 (enExample) |
| CN (1) | CN104781667B (enExample) |
| CA (1) | CA2878126C (enExample) |
| DK (1) | DK2870475T3 (enExample) |
| ES (1) | ES2645431T3 (enExample) |
| IN (1) | IN2014MN02585A (enExample) |
| WO (1) | WO2014006225A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2870475T3 (en) | 2012-07-06 | 2017-09-18 | Innovative Tech In Biological Systems S L | FLUORESCING FUSION POLYPEPTIDE, BIOSENSOR INCLUDING POLYPEPTIDE AND APPLICATIONS THEREOF |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| WO2018141987A1 (en) * | 2017-02-06 | 2018-08-09 | Innovative Technologies In Biological Systems Sl | Fluorescent fusion polypeptide capable of detecting phosphorylation of cellular membrane receptors by grks (g-protein receptor kinases) and/or receptor tyrosine kinases (rtks) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH089640B2 (ja) * | 1994-05-19 | 1996-01-31 | 佑 本庶 | ヒト・インターロイキン−２受容体 |
| US6197928B1 (en) * | 1997-03-14 | 2001-03-06 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
| US7192932B1 (en) * | 1997-04-29 | 2007-03-20 | Lauras As | Use of immunomodulating agents |
| CN1310758A (zh) * | 1998-05-20 | 2001-08-29 | 中外制药株式会社 | 基因克隆的新方法 |
| CA2349720A1 (en) * | 1998-11-12 | 2000-05-18 | Beth Israel Deaconess Medical Center | Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway |
| US7060793B2 (en) * | 1999-05-21 | 2006-06-13 | The Regents Of The University Of California | Circularly permuted fluorescent protein indicators |
| US20070037165A1 (en) * | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US7125660B2 (en) * | 2000-09-13 | 2006-10-24 | Archemix Corp. | Nucleic acid sensor molecules and methods of using same |
| JP2005507650A (ja) * | 2001-08-01 | 2005-03-24 | セロミックス インコーポレイテッド | 新規融合タンパク質及び分子結合に関するアッセイ |
| AU2003270149A1 (en) * | 2002-09-06 | 2004-03-29 | Forschungsverbund Berlin E. V. | Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
| JP4214206B2 (ja) * | 2002-12-10 | 2009-01-28 | 独立行政法人理化学研究所 | Ｆｒｅｔを利用した蛍光指示薬 |
| US7488583B2 (en) * | 2003-09-25 | 2009-02-10 | Odyssey Thera, Inc. | Fragment complementation assays for G-protein-coupled receptors and their signaling pathways |
| GB0411586D0 (en) * | 2004-05-24 | 2004-06-23 | Univ The Glasgow | Fluorescent protein |
| JP2008507995A (ja) * | 2004-08-02 | 2008-03-21 | セルーメン、インコーポレイテッド | 細胞内での分子相互作用の検出方法 |
| EP1997885A1 (en) * | 2007-05-29 | 2008-12-03 | AXXAM S.p.A. | Fluorescent proteins and methods of use thereof |
| EP2193141A1 (en) * | 2007-08-24 | 2010-06-09 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Genetically encoded calcium sensors comprising the c-terminal lobe of troponin c and a fluorescence tag |
| JP2009153399A (ja) * | 2007-12-25 | 2009-07-16 | National Institute Of Advanced Industrial & Technology | 一分子型リアルタイム生物発光イメージングプローブ |
| JP5798489B2 (ja) * | 2009-01-12 | 2015-10-21 | ストロ バイオファーマ， インコーポレイテッド | インビトロタンパク質合成システムを用いて非天然アミノ酸をタンパク質に選択的に導入するためのモノチャージシステム |
| EP2473186A4 (en) * | 2009-08-31 | 2013-07-10 | Ibc Pharmaceuticals Inc | BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF |
| DK2870475T3 (en) | 2012-07-06 | 2017-09-18 | Innovative Tech In Biological Systems S L | FLUORESCING FUSION POLYPEPTIDE, BIOSENSOR INCLUDING POLYPEPTIDE AND APPLICATIONS THEREOF |
-
2013
- 2013-07-08 DK DK13739169.4T patent/DK2870475T3/en active
- 2013-07-08 EP EP13739169.4A patent/EP2870475B1/en active Active
- 2013-07-08 US US14/412,513 patent/US9784728B2/en active Active
- 2013-07-08 WO PCT/EP2013/064400 patent/WO2014006225A1/en not_active Ceased
- 2013-07-08 IN IN2585MUN2014 patent/IN2014MN02585A/en unknown
- 2013-07-08 CN CN201380045944.4A patent/CN104781667B/zh active Active
- 2013-07-08 JP JP2015519247A patent/JP6393260B2/ja active Active
- 2013-07-08 CA CA2878126A patent/CA2878126C/en active Active
- 2013-07-08 ES ES13739169.4T patent/ES2645431T3/es active Active
-
2017
- 2017-09-19 US US15/709,000 patent/US10883981B2/en active Active
- 2017-09-19 US US15/708,971 patent/US10877025B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9784728B2 (en) | 2017-10-10 |
| US10883981B2 (en) | 2021-01-05 |
| US20180003697A1 (en) | 2018-01-04 |
| EP2870475A1 (en) | 2015-05-13 |
| CN104781667A (zh) | 2015-07-15 |
| EP2870475B1 (en) | 2017-06-07 |
| US10877025B2 (en) | 2020-12-29 |
| CN104781667B (zh) | 2017-06-13 |
| CA2878126C (en) | 2022-05-10 |
| US20150185205A1 (en) | 2015-07-02 |
| IN2014MN02585A (enExample) | 2015-07-24 |
| WO2014006225A1 (en) | 2014-01-09 |
| CA2878126A1 (en) | 2014-01-09 |
| DK2870475T3 (en) | 2017-09-18 |
| US20180003698A1 (en) | 2018-01-04 |
| JP6393260B2 (ja) | 2018-09-19 |
| JP2015522582A (ja) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Navarro et al. | Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs | |
| Rizo | Mechanism of neurotransmitter release coming into focus | |
| Benkel et al. | How carvedilol activates β2-adrenoceptors | |
| Davey et al. | TBC1D13 is a RAB35 specific GAP that plays an important role in GLUT4 trafficking in adipocytes | |
| ES2774416T3 (es) | Biosensores para monitorear la localización y el tráfico de biomoléculas en las células | |
| Ward et al. | Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques | |
| ES2832331T3 (es) | Biosensor basado en proteínas que interactúan con gbetagamma para monitorear la activación de proteínas G | |
| Shivnaraine et al. | Single-molecule analysis of the supramolecular organization of the M2 muscarinic receptor and the Gαi1 protein | |
| Rapali et al. | LC8 dynein light chain (DYNLL1) binds to the C-terminal domain of ATM-interacting protein (ATMIN/ASCIZ) and regulates its subcellular localization | |
| Yang et al. | FLIM–FRET-Based Structural Characterization of a Class-A GPCR Dimer in the Cell Membrane | |
| ES2645431T3 (es) | Polipéptido de fusión fluorescente, biosensor que comprende dicho polipéptido y usos de los mismos | |
| Baraniak et al. | Orai channel C-terminal peptides are key modulators of STIM-Orai coupling and calcium signal generation | |
| Duffet et al. | A photocaged orexin-B for spatiotemporally precise control of orexin signaling | |
| Hübner et al. | Evidence for aggregation of protein kinase CK2 in the cell: a novel strategy for studying CK2 holoenzyme interaction by BRET2 | |
| US10435480B2 (en) | Protein coated polymeric substrate | |
| ES2874138T3 (es) | Indicadores de iones potasio genéticamente codificados | |
| Asher et al. | Extreme vetting of dopamine receptor oligomerization | |
| Bosma et al. | Inhibition of constitutive activity of the atypical chemokine receptor ACKR3 by the small-molecule inverse agonist VUF16840 | |
| Shen et al. | Genetically encoded ratiometric indicators for potassium ion | |
| ES2952996T3 (es) | Polipéptido de fusión fluorescente capaz de detectar la fosforilación de receptores de membrana celular por GRK (cinasas receptoras de proteína G) y/o tirosina cinasas receptoras (RTK) | |
| Alvarez-Curto et al. | Defining the functional equivalence of wild-type and chemically engineered G protein-coupled receptors | |
| US20150268247A1 (en) | Assay for Screening of Anti-Viral Compounds That Inhibit Specific Interaction Interfaces Between Cullin5 and an ElonginB/ElonginC/ CBF-beta/HIV-1 Vif Complex | |
| Navarro Brugal et al. | Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs | |
| Hanna | Molecular pharmacological analysis of the human MrgD receptor | |
| New et al. | Chimeric and promiscuous G proteins in drug discovery and the deorphanization of GPCRs |